Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elacestrant - Menarini

Next Previous
Drug Profile

Elacestrant - Menarini

Alternative Names: ORSERDU; RAD 1901

Latest Information Update: 01 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Menarini; Paratek Pharmaceuticals; Radius Health Inc.; SciClone Pharmaceuticals; Stemline Therapeutics
  • Class Amines; Antineoplastics; Ethers; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 negative breast cancer
  • Discontinued Vasomotor symptoms

Most Recent Events

  • 18 Mar 2026 Radius Health Inc. has been acquired and merged into Paratek Pharmaceuticals
  • 22 Jul 2025 Clinical trials in HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT07076680)
  • 09 May 2025 Context Therapeutics terminates a phase Ib/II ELONA trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) because sponsor decided to discontinue the development of onapristone (NCT05618613)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top